Autoinjector improves injection-related tolerability issues in patients with multiple sclerosis - Exploring the new Extaviject™ 30G system for the injection of interferon beta-1b

European Neurological Review

Volumn 5, Issue 2, 2010, Pages 77-81

  Kozubski, Wojciech ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Autoinjector; Disease modifying therapies; Extaviject 30G ; Interferon; Multiple sclerosis; Tolerability

Indexed keywords

EID: 80755144924     PISSN: 17583837     EISSN: 17583845     Source Type: Journal    
DOI: 10.17925/ENR.2010.05.02.77     Document Type: Article

References (30)

1. Hartung HP, Early treatment and dose optimization BENEFIT and BEYOND, J Neurol, 2005;252(Suppl. 3): 344-50.
2. Paolicelli D, Direnzo V, Trojano M, Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis, Biologics, 2009;3:369-76.
3. Kappos L, Freedman MS, Polman CH, et al., Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial, Lancet Neurol, 2009;8:987-97.
4. Kappos L, Freedman MS, Polman CH, et al., Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study, Lancet, 2007;370:389-97.
5. Panitch H, Goodin DS, Francis G, et al., Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial, Neurology, 2002;59: 1496-506.
6. Schwid SR, Thorpe J, Sharief M, et al., Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study, Arch Neurol, 2005;62:785-92.
7. Bayas A, Rieckmann P, Managing the adverse effects of interferon-beta therapy in multiple sclerosis, Drug Saf, 2000;22:149-59.
8. Boyko AN, Clinical effects and tolerability of high-dose, high-frequency recombinant interferon beta-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence, Expert Opin Biol Ther, 2010;10:653-66.
9. Girouard N, Theoret G, Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis, Can J Neurosci Nurs, 2008;30:18-25.
10. Baum K, O'Leary C, Coret Ferrer F, et al., Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b, Mult Scler, 2007;13: 1153-60.
11. Cox D, Stone J, Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis, J Neurosci Nurs, 2006;38:167-71.
12. Turner AP, Williams RM, Sloan AP, et al., Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis, Rehabil Psychol, 2009;54:116-21.
13. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial, Neurology, 1995;45:1277-85.
14. Barkhof F, Polman CH, Radue EW, et al., Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results, Arch Neurol, 2007;64:1292-8.
15. Kappos L, Polman CH, Freedman MS, et al., Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes, Neurology, 2006;67:1242-9.
16. Patti F, Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence, Patient Prefer Adherence, 2010;4:1-9.
17. Treadaway K, Cutter G, Salter A, et al., Factors that influence adherence with disease-modifying therapy in MS, J Neurol, 2009;256:568-76.
18. Cramer JA, Cuffel BJ, Divan V, et al., Patient satisfaction with an injection device for multiple sclerosis treatment, Acta Neurol Scand, 2006;113:156-62.
19. Arendt-Nielsen L, Egekvist H, Bjerring P, Pain following controlled cutaneous insertion of needles with different diameters, Somatosens Mot Res, 2006;23:37-43.
20. Jaber A, Bozzato GB, Vedrine L, et al., A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis, BMC Neurol, 2008;8:38.
21. Freedman SM, Cox D, Rosebrough T, A prospective baseline versus on-treatment study assessing patient perceptions of using a smaller needle when injecting intramuscular interferon beta-1 a (Avonex), J Neurosci Nurs, 2008;40:350-5.
22. Palmon SC, Lloyd AT, Kirsch JR, The effect of needle gauge and lidocaine pH on pain during intradermal injection, Anesth Analg, 1998;86:379-81.
23. Burks JS, The changing face of multiple sclerosis and disease modifying therapies, US Neurol Rev, 2005;51-6.
24. Mikol D, Lopez-Bresnahan M, Taraskiewicz S, et al., A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis, Mult Scler, 2005;11:585-91.
25. Lugaresi A, Durastanti V, Gasperini C, et al., Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study, Clin Neuropharmacol, 2008;31: 167-72.
26. Brochet B, Lemaire G, Beddiaf A, Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices, Rev Neurol (Paris), 2006;162:735-40.
27. Devonshire V, Arbizu T, Borre B, et al., Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study, BMC Neurol, 2010;10:28.
28. Fox EJ, Emerging oral agents for multiple sclerosis, Am J Manag Care, 2010;16:S219-26.
29. Novartis, Extavia: Summary of Product Characteristics, Web Page, 2010, www.medicines.org.uk/emc/medicine/21659/SPC/#PRODUCTINFO.
30. Russell Research Inc., ExtaviJect 30G report, September 2010. Russell Research Inc. One Meadowlands Plaza, Suite 1001, East Rutherford, NJ 07073 USA, Data on file.